J.M. Piulats Rodriguez

KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Johann S. de Bono, Jeffrey C. Goh, Kristiina Ojamaa et al. · Journal of Clinical Oncology · 2018 · 97 citations

Urology, Antitumor Activity, Genitourinary Cancer +13

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · Journal of Clinical Oncology · 2012 · 73 citations

Cancer Management, Pathology, Pharmacotherapy +17

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Oliver Sartor, D.E. Castellano Gauna, Ken Herrmann et al. · Annals of Oncology · 2023 · 66 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · Journal of Clinical Oncology · 2012 · 58 citations

Lba4518 Background, Aa Arm, Pharmacotherapy +16

Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.

J.M. Piulats Rodriguez, María Ochoa de Olza, Manuel Codés et al. · Journal of Clinical Oncology · 2014 · 54 citations

Phase Ii Study, Pharmacotherapy, Dermatology +18